Compumedics Limited

Equities

CMP

AU000000CMP2

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. 09:18:06 2024-06-24 pm EDT 5-day change 1st Jan Change
0.33 AUD -5.71% Intraday chart for Compumedics Limited 0.00% +17.86%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Compumedics on Track to Reach Record Revenue in 2024, But Warns of Earnings Miss MT
Compumedics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Compumedics Expects to Hit Record Fiscal H1 Revenue MT
Compumedics Secures Two Orders for MEG Systems for AU$9.3 Million MT
US FDA Clears Compumedics' Somfit Device for Marketing in the US; Shares Surge 84% MT
Compumedics Limited Provides Revenue Guidance for the Financial Year 2024 CI
Compumedics Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Compumedics Limited's Equity Buyback announced on August 11, 2022, has expired. CI
Compumedics Limited Provides Revenue Guidance for the Year 2023 CI
Compumedics Limited Re-Affirms Earnings Guidance for the Fiscal Year 2023 CI
Compumedics Limited Announces the Resignation of Paul Jensz as Director CI
Compumedics Receives US FDA Clearance for EEG Monitoring Device; Shares Up More than 3% MT
Compumedics Limited Receives 510(K) Clearance from the U.S. Food and Drug Administration for its Okti High-Density EEG Amplication Range CI
Compumedics Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Compumedics Expects 7% Growth in Fiscal H1 Revenue MT
Compumedics Limited Provides Revenue Guidance for the First Half of Fiscal Year 2023 CI
Compumedics Acquires 50% in Austrian Company MT
Compumedics Advances Sales of Sleep Monitoring Device MT
Compumedics Limited Provides Earnings Guidance for the Fiscal Year 2023 CI
Compumedics Limited Reports Earnings Results for the Full Year Ended June 30, 2022 CI
Compumedics Limited announces an Equity Buyback for 4,000,000 shares, representing 2.26% of its issued share capital. CI
Compumedics Limited authorizes a Buyback Plan. CI
Compumedics Limited Revises Earnings Guidance for the Fiscal Year 2022 CI
Compumedics Limited Provides Earnings Guidance for the Year 2022 CI
Tucson Dunn Retires as Director of Compumedics Limited, Effective 31 March, 2022 CI
Chart Compumedics Limited
More charts
Compumedics Limited is a medical device company, which is involved in the development, manufacture, and commercialization of diagnostics technology for sleep, brain and ultrasonic blood flow monitoring applications. Its geographic segments include Americas, Australia and Asia Pacific, and Europe and the Middle East. It sells all of its product offerings in this region, including sleep diagnostic systems, clinical EEG systems, brain monitoring systems, ultra-sonic blood-flow systems, supplies and technical service and support. It provides Sleep Diagnostics and Neurology Diagnostics Solutions. Its products include Compumedics Siesta, Compumedics Somfit, Compumedics Somte PSG and others. It offers Brain Research technologies through the Compumedics Neuroscan brand. Compumedics Neuroscan technologies provide solutions for EEG, ERPs, Source Localization and Functional Neuroimaging. It also provides solutions for sleep applications from high definition 4k full PSG to home sleep testing.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. CMP Stock
  4. News Compumedics Limited
  5. Compumedics on Track to Reach Record Revenue in 2024, But Warns of Earnings Miss